3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
2
Recurrence
1
Neoplasms
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lymphoma
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Hematologic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Endometrioid
1
Breast Neoplasms
1
Advanced Solid Malignancy,
1
Interventions
HhAntag691
2
toripalimab
1
temsirolimus
1
pegfilgrastim
1
pazopanib
1
liposomal doxorubicin
1
enasidenib
1
angiotensin I (1-7)
1
Sunitinib
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Image-Guided
1
Radiotherapy, Conformal
1
Proton Therapy
1
Pharmacogenomic Testing
1
Microarray Analysis
1
Medicare Part B
1
Magnetic Resonance Spectroscopy
1
Immunologic Techniques
1
Gemcitabine
1
Filgrastim
1
Ferrosoferric Oxide
1
Fentanyl
1
Docetaxel
1
Dasatinib
1
Cyproheptadine
1
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
1
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Chondrosarcoma
×
capivasertib
×
Clear all
No trials found.